Cullinan oncology announces u.s. fda clearance of investigational new drug application for cln-978, a novel t-cell engager for the treatment of relapsed/refractory b-cell non-hodgkin lymphoma

Cambridge, mass., jan. 24, 2023 (globe newswire) -- cullinan oncology, inc. (nasdaq: cgem), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced the u.s. food and drug administration (fda) has cleared its investigational new drug (ind) application for cln-978, a cd19/cd3 t-cell engaging antibody construct with a human serum albumin (hsa) binding domain to increase serum half-life. cullinan oncology will initially evaluate cln-978 in a phase 1 trial for the treatment of relapsed/refractory b-cell non-hodgkin lymphoma (b-nhl).
CGEM Ratings Summary
CGEM Quant Ranking